Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02123108 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 59
- Enrollment target
NCT02123108 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 59 participants.
The verdict
NCT02123108, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 59 participants
- Enrollment target
Study Summary
This is an investigator initiated study at the University of California, Los Angeles (UCLA) funded by Novartis looking at using a combination of immunosuppressive drugs in liver transplant patients that are at risk of developing kidney problems. Kidney problems following liver transplants is the most problematic issue facing liver transplant patients today. This study will generate information in this area of high unmet medical need utilizing basiliximab and Myfortic and using a reduced dose of tacrolimus, one of the current standard of care medications, after kidney function has normalized.
Interventions
- DRUG Tacrolimus
- DRUG Basiliximab
- DRUG Mycophenolic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02123108
The ClinicalTrials.gov registry entry for NCT02123108 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tacrolimus is the first listed.
NCT02123108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02123108 about?
NCT02123108 is a clinical study titled "Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation". This is an investigator initiated study at the University of California, Los Angeles (UCLA) funded by Novartis looking at using a combination of immunosuppressive drugs in liver transplant patients that are at risk of developing kidney problems. Kidney problems following liver transplants is the mos...
What is the current status of trial NCT02123108?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2011-01. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02123108?
The interventions under investigation include: Tacrolimus (DRUG), Basiliximab (DRUG), Mycophenolic Acid (DRUG).
Who is sponsoring clinical trial NCT02123108?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.